A Phase II Study of Enzalutamide for Hormone-Positive Salivary Gland Cancers

Full Title

A Phase II Study of Enzalutamide (NSC#766085) for Patients with Androgen Receptor Positive Salivary Cancers (A091404)(CIRB)


Enzalutamide is a drug that blocks the hormone testosterone from binding to a protein on cells called the androgen receptor. It is approved for the treatment of advanced prostate cancer. Researchers believe that blocking the androgen receptor may also slow or stop tumor growth in patients with salivary gland cancers that have the androgen receptor.

Patients in this study whose inoperable or metastatic salivary gland cancer contains the androgen receptor will receive enzalutamide, which is taken by mouth every day.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have salivary gland cancer that cannot be removed surgically or has spread, and contains the androgen receptor.
  • Patients may have received any number of prior therapies, but at least 4 weeks must pass between the completion of previous treatments and entry into the study.
  • Patients may not have previously received enzalutamide.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alan L. Ho at 646-888-4235.